SOMATROPIN
somatropin 600 microgram injection [1 chamber] (&) inert substance diluent [0.25 mL
chamber], 7 dual chamber syringes
SOMATROPIN (10456H)
10456H
Manner of administration:Injection
Restriction
Indication: Short stature and slow growth
Treatment phase: Continuing treatment
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Continuing treatment
Restriction
Indication: Growth retardation secondary to an intracranial lesion, or cranial irradiation
Treatment phase: Continuing treatment
Restriction
Indication: Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants
Treatment phase: Continuing treatment
Restriction
Indication: Biochemical growth hormone deficiency and precocious puberty
Treatment phase: Continuing treatment
Restriction
Indication: Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic
obesity driven growth
Treatment phase: Continuing treatment
Restriction
Indication: Short stature associated with Turner syndrome
Treatment phase: Continuing treatment
Restriction
Indication: Short stature due to short stature homeobox (SHOX) gene disorders
Treatment phase: Continuing treatment
Restriction
Indication: Short stature associated with chronic renal insufficiency
Treatment phase: Continuing treatment
Restriction
Indication: Short stature and poor body composition due to Prader-Willi syndrome
Treatment phase: Continuing treatment
Restriction
Indication: Short stature and slow growth
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Growth retardation secondary to an intracranial lesion, or cranial irradiation
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Biochemical growth hormone deficiency and precocious puberty
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic
obesity driven growth
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature associated with Turner syndrome
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature due to short stature homeobox (SHOX) gene disorders
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature associated with chronic renal insufficiency
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature and poor body composition due to Prader-Willi syndrome
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature and slow growth
Treatment phase: Change of drug
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Change of drug
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 7 | # of repeats: 1 | DPMQ: $145.48 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Genotropin MiniQuick | |||||